Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김용희 | - |
dc.date.accessioned | 2019-11-26T21:14:57Z | - |
dc.date.available | 2019-11-26T21:14:57Z | - |
dc.date.issued | 2017-07 | - |
dc.identifier.citation | MOLECULAR PHARMACEUTICS, v. 14, no. 9, page. 3059-3068 | en_US |
dc.identifier.issn | 1543-8384 | - |
dc.identifier.uri | https://pubs.acs.org/doi/10.1021/acs.molpharmaceut.7b00282 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/114858 | - |
dc.description.abstract | Angiogenesis mainly mediated by upregulation of vascular endothelial growth factor (VEGF) provides a hallmark of rapidly proliferating tumor cells and an essential component of the tumor growth and microenvironment, making it a targetable process for antitumor therapy. RNA interference (RNAi) provides a very effective tool for developing antitumor therapies; however, its application to date has been hampered due to the lack of efficient small interfering RNA (siRNA) delivery systems in vivo. Here, we report a polymeric gene carrier system based on PEGylation of a cationic cysteine-ended 9-mer arginine oligopeptide (CR9C), which provides effective siRNA systemic delivery and specifically suppresses VEGF (siVEGF). The PEG500-CR9C/siVEGF oligopeptoplex provided improved blood circulation, enhanced protection from serum proteases, reduced uptake in the liver and kidneys, enhanced tumor targeting, and down-regulated intratumoral VEGF level, which comprehensively resulted in improved antitumor efficacy without significant toxicity in vivo. PEG500-CR9C has a great potential for safe and efficient siRNA delivery with diverse applications. | en_US |
dc.description.sponsorship | This work was supported by grants from the National Research Foundation of Korea (2014049587, 2015003019) and the Brain Korea 21 plus program (22A20130011095). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | AMER CHEMICAL SOC | en_US |
dc.subject | angiogenesis | en_US |
dc.subject | enhanced permeability and enhanced effect | en_US |
dc.subject | siVEGF delivery | en_US |
dc.subject | PEGylation | en_US |
dc.subject | antitumor therapy | en_US |
dc.title | Enhanced Systemic Anti-Angiogenic siVEGF Delivery Using PEGylated Oligo-D-arginine | en_US |
dc.type | Article | en_US |
dc.relation.no | 9 | - |
dc.relation.volume | 14 | - |
dc.identifier.doi | 10.1021/acs.molpharmaceut.7b00282 | - |
dc.relation.page | 3059-3068 | - |
dc.relation.journal | MOLECULAR PHARMACEUTICS | - |
dc.contributor.googleauthor | Chung, Jee Young | - |
dc.contributor.googleauthor | Ul Ain, Qurrat | - |
dc.contributor.googleauthor | Lee, Hyun Lin | - |
dc.contributor.googleauthor | Kim, So-Mi | - |
dc.contributor.googleauthor | Kim, Yong-Hee | - |
dc.relation.code | 2017007779 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF ENGINEERING[S] | - |
dc.sector.department | DEPARTMENT OF BIOENGINEERING | - |
dc.identifier.pid | yongheekim | - |
dc.identifier.orcid | https://orcid.org/0000-0002-3709-507X | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.